Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Up 290.9% in April

Alterity Therapeutics Limited (NASDAQ:ATHE) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 90,300 shares, a growth of 290.9% from the March 31st total of 23,100 shares. Approximately 1.1% of the shares of the stock are sold short. Based on an average daily volume of 82,300 shares, the days-to-cover ratio is presently 1.1 days.

Wall Street Analyst Weigh In

Separately, Benchmark reissued a “speculative buy” rating and issued a $4.00 target price on shares of Alterity Therapeutics in a report on Thursday, March 7th.

Alterity Therapeutics Stock Up 11.1 %

ATHE traded up $0.25 during trading on Friday, hitting $2.51. 87,873 shares of the stock traded hands, compared to its average volume of 176,674. The business has a 50 day moving average price of $1.96 and a 200 day moving average price of $2.18. Alterity Therapeutics has a twelve month low of $1.55 and a twelve month high of $5.41.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease.